Clinical Trial: Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders

Brief Summary: This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.

Detailed Summary:
Sponsor: Masonic Cancer Center, University of Minnesota

Current Primary Outcome: incidence of graft failure [ Time Frame: 42 days ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

• overall survival [ Time Frame: 6 months, 1 and 2 years ]
• disease free survival [ Time Frame: 6 months, 1 and 2 years ]
  patient no longer needing red blood cell transfusion and/or a hemoglobin S level at that of the donor ( sickle cell disease only)

Original Secondary Outcome: Same as current

Information By: Masonic Cancer Center, University of Minnesota

Dates:
Date Received: June 27, 2014
Date Started: September 2, 2014
Date Completion: August 2021
Last Updated: February 17, 2017
Last Verified: February 2017